Method for treating triple-negative breast cancer using AMPI-109
A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.
1. A method for treating triple-negative breast cancer, comprising:
administering a drug comprising AMPI-109 in an amount effective for treating or preventing triple-negative breast cancer to a patient in need thereof, wherein AMPI-109 has a chemical structure of
2. The method of claim 1 , wherein the drug further comprises an oncolytic agent in an effective amount.
3. The method of claim 2 , wherein the oncolytic agent is at least one selected from the group consisting of doxorubicin and paclitaxel.
4. The method of claim 2 , wherein the oncolytic agent is doxorubicin.
5. The method of claim 2 , wherein the oncolytic agent is paclitaxel.